Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The New Ophthalmic Drug Players

This article was originally published in Start Up

Executive Summary

Unmet medical need and market size continue to drive venture investors to ophthalmic drug plays focused on diseases that blind. This interest is fueled by a stable pool of acquirers and the ability to in-license innovative, clinically validated compounds, providing VCs with a jump start to a potential exit.

You may also be interested in...



Start-Ups, With An Eye On Success In Wet AMD, Tackle The Dry Form

“Early and primitive” is a term frequently used to describe drug development for dry AMD in discussions with experts. Several companies have brought products to Phase II trials, but none has met the efficacy endpoints. A new crop of start-ups is trying, driven by the huge unmet demand and emerging science.

Jumble Of Endpoints For Ophthalmic Surgery Analgesics Coming Into Focus At Panel Session

FDA's Dermatologic and Ophthalmic Drugs Advisory Committee may help provide guidance in the increasingly competitive therapeutic space of postoperative ocular pain.

ONL Therapeutics LLC

ONL Therapeutics LLC is developing an experimental drug to preserve sight in people with detached retinas and other retinal disorders. The start-up aims to leverage understanding about FAS, a cell-based receptor that is a key cause of cell death in photoreceptors. ONL’s small peptide is designed to block the FAS receptor on cells of the eye, to keep the natural ligand from binding and keep the cells alive.

Related Content

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel